Galapagos NV announces positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLORA Phase 2a trial
Highlights:
- Forced vital capacity (FVC) in lungs stabilized over the 12-week treatment period, placebo arm showed expected decline
- Functional respiratory imaging (FRI) confirms FVC data with statistical significance
- GLPG1690 was generally well tolerated
- Rates of discontinuation due to adverse events, as well as serious adverse event rates, were similar between patients on GLPG1690 and placebo.
- First autotaxin inhibitor to show effect in IPF patient trial
- GLPG1690 expected to progress to late stage trial
Galapagos plans to report the FLORA study results at a future medical conference.
No comments:
Post a Comment